The market is expected to witness high adoption rates of systemic therapies, which will provide users an advantage over the conventional therapies. Systemic therapies include immunosuppressive and immunomodulatory therapy,immunoabsorption, allergen-specific immunotherapy, and antimicrobial treatment.In early 2017, the market will witness the launch of the first biologic,dupilumab, which showed a strong dose-dependent efficacy in adults with moderate to severe atopic dermatitis. This drug has been developed jointly by Sanofi and Regeneron and is expected to reach sales of approximately $1.1 billion by 2020.Increasing inorganic growth strategies of vendors will help expand their presence in the market and lead to further consolidations. For instance, LEO Pharma acquired global rights for AstraZeneca’s atopic dermatitis drug tralokinumab, which has already cleared phase IIb trials.

PART 01: Executive summary 6

PART 02: Scope of the report 17

PART 03: Research Methodology 22

PART 04: Introduction 25

Key market highlights 25

PART 05: An overview of atopic dermatitis 27

PART 06: Pipeline analysis 28

PART 07: Market landscape 31

Market overview 31

Market size and forecast 32

PART 08: Five force analysis 33

PART 09: Market segment by ROA 34

Oral ROA 34

Topical ROA 35

Injectable ROA 36

PART 10: Geographical segmentation 37

Atopic dermatitis drugs market in Americas 38

Atopic dermatitis drug market in EMEA 40

Atopic dermatitis drugs market in APAC 42

PART 11: Market drivers 44

Growing prevalence of food allergies exacerbating atopic

dermatitis 44

Growing focus on systemic therapies 44

Increasing use of pharmacological products in

developing countries 45

PART 12: Impact of drivers 46

PART 13: Market challenges 47

Black box warning for Elidel and Protopic 47

Highly genericized market 47

Poor patient adherence due to inadequate information on

drug usage 48

PART 14: Impact of drivers and challenges 49

PART 15: Market trends 50

Increasing M&A leading to market consolidation 50

Launch of first biologic for atopic dermatitis 50

Growing focus on novel drugs 51

PART 16: Vendor landscape 52

Competitive scenario 52

LEO Pharma 53

Mylan 56

Valeant 59

Bayer HealthCare 61

Encore Dermatology 64

PART 17: Appendix 66

List of abbreviations 66

PART 18: Explore Technavio 67